Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

First Posted Date
2005-08-29
Last Posted Date
2022-01-31
Lead Sponsor
Mesoblast, Inc.
Target Recruit Count
32
Registration Number
NCT00136903
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

St. Francis Hospital, Indianapolis, Indiana, United States

🇺🇸

New York Medical College, Valhalla, New York, United States

and more 6 locations

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)

First Posted Date
2005-08-26
Last Posted Date
2012-05-22
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
207
Registration Number
NCT00135811
Locations
🇺🇸

Data Coordinating Center; Cleveland Clinic Foundation; Quantitative Health Sciences; 9500 Euclid Avenue, Cleveland, Ohio, United States

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

First Posted Date
2005-08-24
Last Posted Date
2014-07-02
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
77
Registration Number
NCT00133887
Locations
🇫🇷

Hôpital Edouard Herriot - Service de Dermatologie, Lyon, France

Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia

Phase 1
Completed
Conditions
First Posted Date
2005-07-13
Last Posted Date
2010-09-21
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
75
Registration Number
NCT00119340
Locations
🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

First Posted Date
2005-06-20
Last Posted Date
2017-07-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
595
Registration Number
NCT00114777
Locations
🇺🇸

Sharp Memorial Hospital, San Diego, California, United States

🇺🇸

University Of Alabama At Birmingham, Birmingham, Alabama, United States

🇺🇸

National Institute Of Transplantation, Los Angeles, California, United States

and more 26 locations

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

First Posted Date
2005-06-03
Last Posted Date
2013-07-18
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
10
Registration Number
NCT00112645
Locations
🇺🇸

Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath